Stay updated on ABP 798 vs. Rituximab in RA Clinical Trial
Sign up to get notified when there's something new on the ABP 798 vs. Rituximab in RA Clinical Trial page.

Latest updates to the ABP 798 vs. Rituximab in RA Clinical Trial page
- ChecktodayChange DetectedRevision: v3.3.4 was added and Revision: v3.3.3 was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe Locations section was updated with many new sites across the US and internationally (examples include Alabama, California, Sofia, Harjuma, Hesse, Saxony-Anhalt). Several previously listed locations were removed.SummaryDifference2%

- Check51 days agoChange DetectedA note was added clarifying that PubMed publications are automatically filled and may not all pertain to the study, and the page revision label was updated to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.6%

- Check58 days agoChange DetectedRemoved the site-wide banner about government funding and operating status; the study page content remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check72 days agoChange DetectedThe new screenshot shows only layout and UI adjustments with no changes to core trial details such as study design, eligibility criteria, primary/secondary outcomes, or locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check100 days agoChange DetectedUpdated page now communicates government funding lapse impacts and current NIH Clinical Center operating status, and records a new software version (v3.2.0) while removing the old version reference (v3.1.0).SummaryDifference2%

Stay in the know with updates to ABP 798 vs. Rituximab in RA Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ABP 798 vs. Rituximab in RA Clinical Trial page.